CD47抑制剂的全球市场:市场机会，各适应症临床应用，临床试验趋势(2026年)

全球 CD47 抑制剂市场 - 市场机会、各适应症临床应用及临床试验趋势（2026 年）报告结果及亮点

• 研究方法
• 首个 CD47 抑制剂将于 2028 年获批
• CD47 抑制剂各适应症临床应用及发展前景
• 临床试验中 CD47 抑制剂数量：超过 80 种药物
• CD47 抑制剂临床试验洞察：按公司、国家、适应症和阶段划分
• 全球 CD47 抑制剂市场机会展望：当前趋势与未来前景
• 突破性疗法、快速通道、优先治疗和孤儿药现状洞察

CD47 抑制剂的需求抑制剂及其报告意义

新型癌症治疗的探索重点在于CD47通路，这是一个免疫检查点，使癌症能够逃避免疫系统的攻击。 CD47可以被描述为癌细胞发出的 "别吃我" 的信号，以防止被巨噬细胞（先天免疫系统的关键组成部分）清除。这使得CD47成为多种血液系统恶性肿瘤和实体肿瘤的有希望的治疗标靶。虽然PD-1/PD-L1抑制剂已取得显着进展，但许多患者对其治疗无效或产生抗药性。

本报告全面回顾了CD47标靶治疗的全球市场，涵盖了目前正在探索的各种药物，包括单株抗体、双特异性抗体、抗体-药物偶联物、奈米抗体和小分子。本书涵盖了不断发展的临床前景、标靶CD47的理论基础以及这类新型疗法的商业机会。本报告整合了正在进行的临床试验、技术发展和关键参与者的信息，为利益相关者（从研发专业人员到投资者和製药行业领导者）提供了他们在这个快速发展的领域中探索所需的知识。

本报告关于CD47标靶药物临床试验的见解

本报告的核心是一份全面的临床开发项目列表，这些项目评估了针对多种癌症适应症的CD47标靶药物。报告列出了从I期到III期的临床试验，并提供了地理分布、资助机构、研究设计和终点资讯。正在进行的针对非何杰金氏淋巴瘤和急性髓性白血病等血液系统恶性肿瘤以及肺癌、结直肠癌、卵巢癌和乳腺癌等实体瘤的研究，显示全球对CD47标靶疗法的广泛兴趣。

本报告强调了人们日益增长的观点，即CD47抑制剂与其他免疫疗法、化疗或标靶疗法联合使用效果最佳。本报告探讨了临床试验终点，例如总存活期、无恶化存活期和缓解率，以及安全性和耐受性评估——所有这些关键参数都决定监管部门的批准和临床应用。这些试验的新发现凸显了CD47阻断疗法的前景和局限性，尤其是在控制贫血和血小板减少等脱靶毒性方面。

本节简要介绍目前的临床进展，以帮助决策者了解CD47标靶疗法的竞争态势，以及临床试验结果如何为CD47标靶疗法的未来发展策略提供参考。

从事CD47标靶疗法研发的重点公司

CD47治疗领域以密集的研发活动为特征，无数公司正在推动创新，力求达到新的高度。本报告介绍了投资 CD47 研究的领先生物技术和製药公司，包括吉利德科学 (Gilead Sciences)、ALX Oncology、天境生物 (I-Mab Biopharma)、康方生物 (Akeso Biopharma)、Phanes Therapeutics 和 Liminatus Pharma。这些公司正在研究一系列疗法，从第一代单株抗体到下一代双特异性抗体和小分子抑制剂，旨在提高特异性、最大限度地减少副作用并最大限度地提高疗效。

本报告探讨了这些公司如何利用专有技术实现差异化，例如用于限制免疫相关毒性的 Fc 区工程、增强肿瘤选择性和亲和力的策略，以及奈米颗粒和载体等新型递送系统。报告还重点介绍了推动 CD47 科学临床应用的策略联盟和许可协议。了解竞争格局和技术差异化因素，有助于利害关係人预测，随着越来越多的疗法接近监管里程碑，哪些进入者最有可能占市场主导地位。

一份揭示CD47标靶治疗未来方向的报告

本报告展望未来，并预测了影响CD47标靶治疗方向的几个关键趋势。安全性和选择性仍然是主要课题。未来的治疗可能旨在优化免疫参与，以最佳方式根除肿瘤，同时降低血液学毒性。同时针对CD47和肿瘤特异性抗原的双特异性抗体和多功能融合蛋白的出现，可能会改善治疗方案和疗效。

能够根据CD47表达和免疫微环境对患者进行准确分层的生物标记指导策略可能会变得越来越重要。这种个人化策略可以提高缓解率，并避免不必要地接触潜在的毒性疗法。将CD47抑制剂与传统免疫疗法或化疗结合的联合疗法很可能成为标准治疗方法，尤其是对于难治性癌症。

此外，从血液系统恶性肿瘤到实体肿瘤的扩展代表着巨大的成长机会。奈米技术和基因编辑等药物递送平台的发展将带来新的治疗机会，并有可能实现长期缓解或治癒。随着后期临床数据的涌现和监管途径的日益清晰，CD47靶向治疗市场有望实现显着增长，并为全球癌症免疫治疗的未来铺平道路。

目录

第1章 调查手法

第2章 CD47 作为癌症免疫治疗的新标靶

第3章 CD47临床应用和各适应症的开发展望

• 固体癌
  • 乳癌
  • 消化器官癌症
  • 肺癌症
  • 泌尿生殖系统及妇产科癌症
  • 头颈椎癌症
• 造血恶性肿瘤
  • 淋巴瘤
  • 白血病
  • 多发性骨髓瘤
  • 骨髓发育不良症候群
• 微生物感染疾病
• 心血管疾病

第4章 全球CD47抑制剂的临床实验平台概要

• 各国
• 各企业
• 各适应症
• 各期
• 优先各状态

第5章 CD47抑制剂的临床试验:企业，国家，适应症，各期

• 研究
• 前临床
• 第一阶段
• 第一/二阶段
• 第二阶段
• 第二/三阶段
• 第三阶段

第6章 全球CD47抑制剂市场机会展望

• 目前市场概要
• 未来展望和机会

第7章 CD47抑制剂临床开发与各国的趋势

• 中国
• 美国
• 韩国
• 澳洲
• 加拿大

第8章 全球CD47抑制剂市场动态

第9章 竞争情形

• Adagene
• Akeso
• ALX Oncology
• Chia Tai Tianqing Pharmaceutical Group
• EpicentRx
• ImmuneOncia Therapeutics
• ImmuneOnco Biopharma
• Light Chain Bioscience
• Phanes Therapeutics
• Virtuoso Therapeutics

Global CD47 Inhibitors Drug Market Opportunity, Clinical Application By Indications & Clinical Trials Insight 2026 Report Findings & Highlights:

• Research Methodology
• First CD47 Inhibitor Drug Approval By 2028
• CD47 Clinical Application & Development Outlook By Indication
• Number Of CD47 Inhibitors Drugs In Clinical Trials: > 80 Drugs
• CD47 Inhibitors Clinical Trials Insight By Company, Country, Indication & Phase
• Global CD47 Inhibitor Drug Market Opportunity Outlook: Current Trends & Future Scenario
• Breakthrough therapy, Fast Track, PRIME & Orphan Status Insight

Need For CD47 Targeted Therapies & Why This Report

The quest for new cancer treatments has highlighted the CD47 pathway, an immune checkpoint that enables cancer to escape attack by the immune system. CD47 can be called the "don't eat me" signal that cancer cells emit to prevent elimination by macrophages, a key element of the innate immune system. This renders CD47 a very promising therapeutic target for a broad panel of hematologic malignancies and solid tumors. While PD-1/PD-L1 inhibitors have shown significant progress, numerous patients do not respond or become resistant, emphasizing the pressing need for new modalities such as CD47 blockade to further expand the reach of immunotherapy.

This report provides an exhaustive review of the worldwide market for CD47 targeted therapy, covering the heterogeneity of drug formats being explored, such as monoclonal antibodies, bispecific antibodies, antibody drug conjugates, nanobodies and small molecules. It covers the changing clinical landscape, the rationale for targeting CD47, and commercial opportunity for this new class of therapy. Through aggregating information regarding active clinical trials, technological developments, and major players, the report empowers stakeholders from researchers and clinicians to investors and pharmaceutical industry leaders with the understanding required to navigate this quickly developing space.

CD47 Targeted Therapies Clinical Trials Insight Covered In the Report

At the epicenter of this report is an exhaustive list of clinical development programs assessing CD47-targeted therapies for multiple cancer indications. It lists trials ranging from Phase-I to Phase-III stages, offering information on their geographical distribution, sponsoring agencies, trial design, and endpoints. The global view showcases the extensive interest in targeting CD47 therapeutically, with ongoing studies covering hematologic malignancies like non-Hodgkin lymphoma and acute myeloid leukemia and solid tumors like lung, colorectal, ovarian, and breast cancers.

The report covers trials assessing combination approaches, which is a sign of the increasing belief that CD47 inhibitors are best utilized when combined with other immunotherapies, chemotherapies, or targeted treatments. The report offers an evaluation of trial endpoints such as overall survival, progression-free survival, and response rates, together with safety and tolerability measurements, all of which are major parameters determining regulatory approvals and clinical adoption. Emerging reports from these trials highlight the potential and pitfalls of CD47 blockade, specifically in controlling on-target toxicities such as anemia and thrombocytopenia.

By presenting a snapshot of current clinical advances, this section equips decision-makers to grasp where the therapeutic contenders are at and how clinical trial results are informing future development trajectories for CD47-targeted therapies.

Key Companies Engaged In R&D For CD47 Targeted Therapies

The therapeutic space of CD47 is characterized by high research and development activity spearheaded by a myriad of companies driving innovation to new heights. This report identifies leading biotech and pharma companies that are committed to investing in CD47 research such as Gilead Sciences, ALX Oncology, I-Mab Biopharma, Akeso Biopharma, Phanes Therapeutics, and Liminatus Pharma. These firms are investigating a range of therapeutic modalities, from first-generation monoclonal antibodies to next-generation bispecifics and small-molecule inhibitors aimed at enhancing specificity, minimizing side effects, and maximizing efficacy.

The report discusses how these firms are differentiating themselves based on proprietary technologies such as engineered Fc regions to restrict immune-related toxicity or strategies to enhance tumor selectivity and binding, or new delivery systems such as nanoparticles and vectors. It also addresses strategic alliances and licensing agreements that are propelling the translation of CD47 science into clinical assets. A grasp of the competitive landscape and technological differentiators facilitates stakeholders to estimate which players are best suited to rule the market as more therapies near regulatory milestones.

Report Suggesting Future Direction Of CD47 Targeted Therapies Treatment

Looking to the future, the report predicts a number of major trends that will shape the course of CD47-targeting therapies. Safety and selectivity are still major challenges; future therapies will most probably aim to hone immune engagement for optimal tumor eradication with decreased hematologic toxicities. The emergence of bispecific antibodies and multi-functional fusion proteins with the ability to target CD47 as well as tumor-specific antigens simultaneously is likely to enhance therapeutic windows and outcomes.

Biomarker-guided strategies will become increasingly prominent, allowing for the accurate stratification of patients according to CD47 expression and immune microenvironment. Such a personalized strategy can enhance response and prevent unnecessary exposure to potentially toxic treatments. Combination therapies combining CD47 inhibitors with conventional immunotherapies and chemotherapy are likely to become the norm, particularly in the case of therapy-resistant cancers.

In addition, the expansion into solid tumors from hematologic malignancies is a huge opportunity for growth. Inventions in drug delivery platforms, such as nanotechnology and gene editing, could realize new therapeutic opportunities, potentially leading to long-term remission or cure. With late-stage clinical data on the horizon and regulatory pathways becoming more defined, the CD47-targeted therapy market stands to enjoy huge growth, setting the future of cancer immunotherapy on a global level.

Table of Contents

1. Research Methodology

2. CD47 As Novel Cancer Immunotherapy Target

3. CD47 Clinical Application & Development Outlook By Indication

• 3.1 Solid Cancers
  • 3.1.1 Breast Cancer
  • 3.1.2 Gastrointestinal Cancer
  • 3.1.3 Lung Cancer
  • 3.1.4 Urogenital & Gynecologic Cancers
  • 3.1.5 Head & Neck Cancer
• 3.2 Hematological Malignancies
  • 3.2.1 Lymphoma
  • 3.2.2 Leukemia
  • 3.2.3 Multiple Myeloma
  • 3.2.4 Myelodysplastic syndrome
• 3.3 Microbial Infections
• 3.4 Cardiovascular Diseases

4. Global CD47 Inhibitors Drug Clinical Pipeline Overview

• 4.1 By Country
• 4.2 By Company
• 4.3 By Indication
• 4.4 By Phase
• 4.5 By Priority Status

5. CD47 Inhibitors Clinical Trials Insight By Company, Country, Indication & Phase

• 5.1 Research
• 5.2 Preclinical
• 5.3 Phase I
• 5.4 Phase I/II
• 5.5 Phase II
• 5.6 Phase II/III
• 5.7 Phase III

6. Global CD47 Inhibitor Drug Market Opportunity Outlook

• 6.1 Current Market Overview
• 6.2 Future Outlook & Opportunities

7. CD47 Inhibitor Drugs Clinical Developments & Trends By Country

• 7.1 China
• 7.2 US
• 7.3 South Korea
• 7.4 Australia
• 7.5 Canada

8. Global CD47 Inhibitors Market Dynamics

• 8.1 Favorable Parameters
• 8.2 Market Restraints

9. Competitive Landscape

• 9.1 Adagene
• 9.2 Akeso
• 9.3 ALX Oncology
• 9.4 Chia Tai Tianqing Pharmaceutical Group
• 9.5 EpicentRx
• 9.6 ImmuneOncia Therapeutics
• 9.7 ImmuneOnco Biopharma
• 9.8 Light Chain Bioscience
• 9.9 Phanes Therapeutics
• 9.10 Virtuoso Therapeutics

List of Figures

• Figure 2-1: CD47-SIRPa Axis & Its Role In Immune Evasion
• Figure 2-2: CD47 Blockade - Mechanisms Of Action
• Figure 2-3: CD47 Targeted Therapies - Development Timeline
• Figure 3-1: PRE-I-SPY-PI Phase I Study (NCT05868226) - Initiation & Completion Year
• Figure 3-2: I-SPY 2 Phase I Study (NCT01042379) - Initiation & Completion Year
• Figure 3-3: ZWI-ZW25-204 1/2 Phase I Study (NCT05027139) - Initiation & Completion Year
• Figure 3-4: LCB-1801-001 Phase I Study (NCT05403554) - Initiation & Completion Year
• Figure 3-5: AK112-206 Phase II Study (NCT05382442) - Initiation & Completion Year
• Figure 3-6: AT148006 Phase II/III Study (NCT05002127) - Initiation & Completion Year
• Figure 3-7: TWINPEAK Phase I/II Study (NCT05482893) - Initiation & Completion Year
• Figure 3-8: AK104-219 Phase II Study (NCT05960955) - Initiation & Completion Year
• Figure 3-9: AK117-202 Phase I/II Study (NCT05214482) - Initiation & Completion Year
• Figure 3-10: SKYBRIDGE Phase I/II Study (NCT05652686) - Initiation & Completion Year
• Figure 3-11: HCC 21-193 Phase I/II Study (NCT05652686) - Initiation & Completion Year
• Figure 3-12: HCB101-101 Phase I Study (NCT05892718) - Initiation & Completion Year
• Figure 3-13: NCI-2021-08492 Phase I/II Study (NCT05025800) - Initiation & Completion Year
• Figure 3-14: NCI-2022-06277 Phase II Study (NCT05507541) - Initiation & Completion Year
• Figure 3-15: AK117-104 Phase I/II Study (NCT04980885) - Initiation & Completion Year
• Figure 3-16: AK117-206 Phase I/II Study (NCT06387420) - Initiation & Completion Year
• Figure 3-17: BHARAT-1 Phase I Study (NCT05607199) - Initiation & Completion Year
• Figure 3-18: MagnetisMM-20 Phase I Study (NCT05675449) - Initiation & Completion Year
• Figure 3-19: 21-122 Phase I Study (NCT05139225) - Initiation & Completion Year
• Figure 3-20: U1111-1244-2598 Phase I/II Study (NCT04643002) - Initiation & Completion Year
• Figure 3-21: AK117-103 Phase I/II Study (NCT04900350) - Initiation & Completion Year
• Figure 3-22: AK117-205 Phase II Study (NCT06196203) - Initiation & Completion Year
• Figure 4-1: Global - Number of CD47 Inhibitor Drugs Clinical Trial By Country, 2025 - 2026
• Figure 4-2: Global - Number of CD47 Inhibitor Drugs In Clinical Pipeline By Company, 2025 - 2026
• Figure 4-3: Global - Number of CD47 Inhibitor Drugs In Clinical Pipeline By Indication, 2025 - 2026
• Figure 4-4: Global - Number of CD47 Inhibitor Drugs In Clinical Pipeline By Phase, 2025 - 2026
• Figure 4-5: Global - Number of CD47 Inhibitor Drugs In Clinical Pipeline By Priority Status, 2025 - 2026
• Figure 6-1: CD47 Targeted Therapy - Future Opportunities
• Figure 8-1: Global CD47 Inhibitors Market - Drivers & Opportunities
• Figure 8-2: Global CD47 Inhibitors Market - Challenges & Restraints